Schizophrenia Trial, Recruiting NCT05956327 Sponsor: LMU Klinikum Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05956327
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with schizophrenia according to recognised medical diagnostic standards (ICD-10 and DSM-5)
  • People whose schizophrenia symptoms are at a relatively stable and low level, as measured by a standard symptom rating scale (a total score of 75 or below on the PANSS)
  • People who have given written agreement to take part in the study voluntarily
  • Women of childbearing age who are using reliable contraception
  • People who have been taking antipsychotic medication (one or two medications, including long-acting injectable forms) chosen to suit their individual needs, following current treatment guidelines, with the same medication and dose kept stable for at least 2 weeks before joining the study. A small amount of additional short-term medication for agitation or sleep problems may also be acceptable, within set dose limits

Who may not be able to join:

  • People assessed by an independent psychiatrist as lacking the reliability or mental capacity to participate
  • People who test positive for illegal drugs in a urine test (note: benzodiazepines are an exception to this)
  • People who are considered to be at immediate risk of suicide
  • People who have another significant psychiatric condition identified through structured diagnostic testing
  • People who have another significant neurological or other medical condition
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Falkai, Prof. Dr., Director of the Department of Psychiatry and Psychotherapy, University Hospital, LMU

Phone: +49 89 4400 55537

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
LMU Klinikum
Registry
ClinicalTrials.gov
Start date
29 September 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Hippocampal volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov